iX Biopharma Ltd – Gaining altitude with significant approvals September 25, 2026

Brief Overview

The US Secretary of Health and Human Services (HHS) has declared an Emergency Use Authorisation for drugs to treat moderate-to-severe acute pain in military injuries, following a military emergency determination by the US Secretary of War in July 2026. This declaration represents a significant step towards FDA approval and commercialisation for iX Biopharma’s Wafermine product. Phillip Securities Research maintains its BUY recommendation with an unchanged target price of S$1.00.

Investment Positives

The HHS declaration creates a substantial positive development for iX Biopharma’s prospects. The company now benefits from inherent endorsement by two US government departments – HHS and DOW – that Wafermine is suitable for Emergency Use Authorisation approval. This dual departmental support significantly strengthens the regulatory pathway for the drug.

The Emergency Use Authorisation pathway offers compelling commercial advantages. If granted, EUA will allow Wafermine to be deployed for authorised use by US military personnel before receiving full FDA approval. Crucially, commercialisation via EUA will generate income for iX Biopharma while the Phase 3 clinical programme continues, providing revenue streams during the lengthy approval process.

The financial foundation for development remains solid, with iX Biopharma having received a sole-source US$41 million award from the Department of War (DOW) in February 2026 specifically to develop Wafermine for treating moderate-to-severe acute pain. Additionally, the Phase 3 trials will be fully funded by the DOW, removing significant financial burden from the company.

Production capabilities are set to expand systematically, with the US production line expected to commence in 1Q27, followed by three additional production lines in 2Q27, positioning the company for scaled commercialisation.

Outlook

The regulatory timeline remains clearly defined with major milestones unchanged. The company expects to complete the Wafermine EUA submission by 4Q26, with EUA approval anticipated in 1Q27 and EUA production beginning in 2Q27. Phase 3 trial approval is also expected in 2Q27, maintaining the structured development pathway.

Recommendation & Target Price

Phillip Securities Research maintains a BUY recommendation for iX Biopharma Ltd with an unchanged DCF SOTP target price of S$1.00. The recommendation and forecast remain unchanged despite the positive regulatory developments.

Frequently Asked Questions

Q: What is the significance of the HHS declaration for iX Biopharma?

A: The declaration creates an emergency use pathway for drugs treating moderate-to-severe acute pain in military casualties and represents inherent endorsement by two US government departments that Wafermine is suitable for EUA approval.

Q: How will Emergency Use Authorisation benefit the company financially?

A: EUA approval will allow commercialisation and income generation for iX Biopharma while Phase 3 clinical trials continue, providing revenue before full FDA approval.

Q: What funding has iX Biopharma received for Wafermine development?

A: The company received a sole-source US$41 million award from the Department of War in February 2026 to develop Wafermine for treating moderate-to-severe acute pain.

Q: When are the key milestones expected?

A: Major milestones include Wafermine EUA submission (4Q26), EUA approval (1Q27), EUA production (2Q27), and Phase 3 trial approval (2Q27).

Q: What are the production expansion plans?

A: The US production line is expected to commence in 1Q27, with three additional production lines starting in 2Q27.

Q: Who will fund the Phase 3 trials?

A: The Phase 3 trials will be fully funded by the Department of War.

Q: What is the current investment recommendation?

A: Phillip Securities Research maintains a BUY recommendation with an unchanged target price of S$1.00.

This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.

Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.

Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.

Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

About the author

Paul Chew

Paul has more than 25 years of experience as a fund manager and sell-side analyst. He currently covers sectors such as healthcare, electronics, telecommunications, conglomerates, small caps, and strategy.

He graduated from Monash University and has completed both his Chartered Financial Analyst and Australian CPA programme.

Palo Alto Networks Inc – Highest Sales Growth in 9 Years